# VYD2311 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vyd2311

> The next catalyst for VYD2311, sponsored by Invivyd, Inc. (IVVD), is its primary completion, June 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VYD2311 |
| Codes | VYD2311 |
| Sponsor | Invivyd, Inc. (IVVD) https://sec-api.dev/companies/ivvd/catalysts |
| Indications | [COVID-19](https://sec-api.dev/indications/covid-19), [Long COVID](https://sec-api.dev/indications/long-covid) |
| Modality |  |
| FDA designations | accelerated, fast track |

## Timeline

### Q4 2024: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-257993): "Next generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024" https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-257993): "First-in-human clinical trial dosing began in August 2024 assessing PK and safety with anticipated preliminary data readout late Q4 2024 with additional clinical readouts throughout 2025" https://www.sec.gov/Archives/edgar/data/1832038/000119312524257993/d894288dex992.htm

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-03-05, last confirmed 2026-08-13.
- SEC Form 10-Q (accession 0001193125-26-349215): "In December 2025, the Company initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/ivvd-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-349215): "In December 2025, we initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via IM injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/ivvd-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-222779): "In December 2025, the Company initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526222779/ivvd-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-222779): "In December 2025, we initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via IM injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526222779/ivvd-20260331.htm
- SEC Form 10-K (accession 0001193125-26-092547): "In December 2025, we initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via IM injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm
- SEC Form 10-K (accession 0001193125-26-092547): "In December 2025, the Company initiated DECLARATION, which is a Phase 3 randomized, triple-blind, placebo-controlled clinical trial to evaluate VYD2311 safety and efficacy in prevention of symptomatic, RT-PCR-confirmed COVID-19 at three months, with either a single dose or monthly doses of VYD2311, each administered via intramuscular injection, compared to placebo." https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm

### mid-2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-01-08, last confirmed 2026-03-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-092528): "Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025" https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-006997): "Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025" https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/d93103dex991.htm

### Jun 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-08-13, last confirmed 2026-08-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349193): "LIBERTY: In June 2026, Invivyd announced first participants dosed and completion of enrollment in LIBERTY, a Phase 3 clinical trial to evaluate the safety and tolerability of VYD2311 antibody versus mRNA COVID vaccine and to characterize the safety and immunology of antibody and mRNA vaccine co-administration." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm

### Q3 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: COVID-19.
- First seen 2026-01-08, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222762): "Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3 2026" https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex991.htm
- ClinicalTrials.gov: "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." https://clinicaltrials.gov/study/NCT07655180
- Press release filed with the SEC (EX-99) (accession 0001193125-26-092528): "Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025" https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-006997): "Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025" https://www.sec.gov/Archives/edgar/data/1832038/000119312526006997/d93103dex991.htm

### August 15, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: COVID-19.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07655180 (Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-15 (ACTUAL); Lead Sponsor Invivyd, Inc.." https://clinicaltrials.gov/study/NCT07655180

### September 29, 2026: topline data readout

- Status: completed, met. Date confidence: exact.
- First seen 2025-10-06, last confirmed 2026-09-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-406007): "NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine COMIRNATY® (mRNA-based COVID-19 vaccine, COVID-19 mRNA vaccine, or COVID vaccine), and (3) VYD2311 co-administered with mRNA-based COVID-19 vaccine." https://www.sec.gov/Archives/edgar/data/1832038/000119312526406007/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-377493): "Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312526377493/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268057): "REVOLUTION, Invivyd's development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials, which are expected to begin around year-end 2025; top-line data anticipated mid-2026" https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349193): "The LIBERTY study is now fully dosed, with top-line data anticipated in late Q3 2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-222762): "DECLARATION reduced visits, and inclusion of pregnant & breastfeeding womenInitiation pending DECLARATION Topline data expected Q3 2026 On track to initiate Q2 2026 success" https://www.sec.gov/Archives/edgar/data/1832038/000119312526222762/d120795dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-329488): "Top-line data from the trial are expected mid-2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312525329488/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-230898): "The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated mid-2026" https://www.sec.gov/Archives/edgar/data/1832038/000119312525230898/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-230898): "Invivyd intends to initiate these clinical trials as soon as practicable, with the goal of year-end 2025 trial start and top-line data mid-2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312525230898/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349193): "LIBERTY study fully dosed with top-line data anticipated in late Q3 2026" https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349193): "DECLARATION is designed to support potential Biologics License Application (BLA) submission, with top-line data planned later in Q3 2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349193/ivvd-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-092528): "DECLARATION is part of Invivyd's REVOLUTION clinical program aimed at establishing monoclonal antibody prophylaxis for prevention of COVID; top-line data are expected mid-2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm
- SEC Form 10-Q (accession 0001193125-26-349215): "DECLARATION is designed to support potential Biologics License Application ("BLA") submission, with top-line data planned later in the third quarter of 2026." https://www.sec.gov/Archives/edgar/data/1832038/000119312526349215/ivvd-20260630.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07899346 (Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Invivyd, Inc.." https://clinicaltrials.gov/study/NCT07899346

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07899346 (Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Invivyd, Inc.." https://clinicaltrials.gov/study/NCT07899346

## Same indication

- [Anktiva](https://sec-api.dev/pdufa/anktiva) (IBRX)
- [Bezisterim](https://sec-api.dev/pdufa/bezisterim) (BIVI)
- [Bnt162b2 (2025/2026 formulation)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-formulation) (BNTX)
- [Bnt162b2 (2025/2026 recommended sars-cov-2 strain)](https://sec-api.dev/pdufa/bnt162b2-2025-2026-recommended-sars-cov-2-strain) (BNTX)
- [Bnt162b2 vaccine](https://sec-api.dev/pdufa/bnt162b2-vaccine) (BNTX)
- [Cic vaccine co-formulated tniv2 , sarscov-2 rs and matrix-m adjuvant](https://sec-api.dev/pdufa/cic-vaccine-co-formulated-tniv2-sarscov-2-rs-and-matrix-m-adjuvant) (NVAX)
- [MRNA-1083](https://sec-api.dev/pdufa/mrna-1083) (MRNA)
- [N-803 (il-15 superagonist)](https://sec-api.dev/pdufa/n-803-il-15-superagonist) (IBRX)
- [Nirmatrelvir](https://sec-api.dev/pdufa/nirmatrelvir) (PFE)
- [Nvx-cov2705](https://sec-api.dev/pdufa/nvx-cov2705) (SNY)
- [VYD2311-SD](https://sec-api.dev/pdufa/vyd2311-sd) (IVVD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vyd2311.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VYD2311 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vyd2311

```bibtex
@misc{secapidev_pdufa_vyd2311_20261116,
  title        = {VYD2311 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vyd2311}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vyd2311_20261116","title":"VYD2311 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vyd2311","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
